Avalo Therapeutics, Inc. (AVTX) vs Geron Corporation (GERN)

Avalo Therapeutics, Inc. and Geron Corporation are both Biotechnology companies. Avalo Therapeutics, Inc. and Geron Corporation are of similar size ($843.1M and $815.9M). Geron Corporation grew revenue faster over the last twelve months: 24.4% against −92.7%. Avalo Therapeutics, Inc. has the higher net margin (0.00% vs −33.1%) and the lower return on invested capital (−118.2% vs −89.9%). Across the 18 metrics below, Geron Corporation leads on 11 and Avalo Therapeutics, Inc. on 7.

Valuation

Metric AVTX GERN Biotechnology median
P/E n/m n/m 7.88
P/S 540.92 4.13 11.47
P/B 1.50 3.87 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 221.48 3.59 10.73
Earnings yield (28.25%) (8.37%) (28.84%)
Free cash flow yield (20.63%) (13.58%) (23.03%)

Profitability

Metric AVTX GERN Biotechnology median
Gross margin 64.72% 93.51% 65.16%
Operating margin 0.00% (25.31%) 0.00%
Net margin 0.00% (33.05%) 0.00%
Free cash flow margin 0.00% (56.10%) 0.00%
Return on equity (36.27%) (28.28%) (57.72%)
Return on assets (32.50%) (12.59%) (49.22%)
Return on invested capital (118.21%) (89.85%) 0.00%

Growth

Metric AVTX GERN Biotechnology median
Revenue growth (TTM) (92.65%) 24.39% 5.64%
EPS growth (last fiscal year) (24.62%) 51.85% —
Revenue growth, 5-year CAGR (61.19%) 273.49% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AVTX GERN Biotechnology median
Debt to equity 0.00 0.55 0.00
Current ratio 19.31 6.92 4.73
Net debt to EBITDA 1.36 3.28 0.96

Dividend

Metric AVTX GERN Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric AVTX GERN Biotechnology median
Market cap 843.06m 815.94m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack